Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab (MOR202) in IgA Nephropathy

PHASE2CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

August 31, 2021

Primary Completion Date

February 6, 2023

Study Completion Date

May 6, 2024

Conditions
Immunoglobulin A (IgA) Nephropathy
Interventions
DRUG

Felzartamab

anti-CD38+ monoclonal antibody

OTHER

Placebo

Placebo comparator

Trial Locations (60)

121

JSC Evex Hospitals, Tbilisi

144

L. Managadze National Center of Urology LTD, Tbilisi

Tbilisi State Medical University's and Ingorokva's University Clinic of High Medical Technologies, Tbilisi

220

Far Eastern Memorial Hospital, Taipei

407

Taichung Veterans General Hospital, Taichung

1680

Diagnostic- Consultative Center Convex EOOD, Sofia

3000

UZ Leuven Hospital, Leuven

3400

Medical Center Hera EOOD, Montana, Montana

4000

CHU Sart Tilman Hospital, Liège

Medical Center Hipokrat- N EOOD, Plovdiv

4064

Core Research Group, Milton

4234

St Frances Cabrini Medical Center and Cancer Institute, Santo Tomas

5030

Konkuk University Medical Center, Seoul

8003

Hospital del Mar, Barcelona

8025

Fundacio Puigvert, Badalona

8035

Hospital Universitario Vall d'Hebron - PPDS, Barcelona

8036

Hospital Clinic de Barcelona, Barcelona

8916

Hospital Universitario Germans Trias i Pujol, Badalona

10034

Fakultni nemocnice Kralovske Vinohrady Hospital, Prague

11080

Clinical Hospital Center Bezanijska Kosa, Belgrade

13620

Seoul National University Bundang Hospital, Seongnam

16499

Ajou University Hospital, Suwon

18000

University Clinical Center Nis, Niš

21000

Clinical Centre of Vojvodina, Novi Sad

23561

Taipei Medical University Shuang Ho Hospital, New Taipei City

25198

Hospital Universitari Arnau de Vilanova, Lleida

30625

Medizinische Hochschule Hannover, Hanover

37000

General Hospital Krusevac, Kruševac

45122

Universitätsklinikum Essen, Essen

46002

Municipal Non-profit Enterprise Ternopil Regional Clinical Hospital of Ternopil Regional Council, Ternopil

55902

Mayo Clinic Hospital - Methodist Campus, Rochester

69600

Municipal Nonprofit Enterprise Zaporizhzhia Regional Clinical Hospital Zaporizhzhia Regional Council, Zaporizhzhia

79935

MedResearch INC, El Paso

95687

Amicis Research Center, Vacaville, Vacaville

93030-5822

FOMAT Medical Research - FOMAT - HyperCore - PPDS, Oxnard

Unknown

Sunshine Hospital - Australia, Saint Albans

Imelda VZW, Bonheiden

Regionaal Ziekenhuis Jan Yperman VZW, Ieper

University Multiprofile Hospital for Active Treatment, Stara Zagora

Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz

University Malaya Medical Centre, Pantai

Clinical Hospital Centar Zvezdara, Belgrade

The Catholic University of Korea, Uijeongbu St. Mary's Hospital, Uijeongbu-si

Hospital Universitari de Girona Dr Josep Trueta, Girona

Hospital Ruber Juan Bravo (Grupo Quironsalud), Madrid

"Communal Nonprofit Enterprise Kyiv City Center of Nephrology and Dialysis", Kyiv

State Institution Institute of Nephrology of NAMS of Ukraine, Kyiv

Kings College Hospital, London

741 01

Nemocnice AGEL Novy Jicin a.s, Nový Jicín

775 20

Eticka komise Fakultni nemocnice Olomouc, Olomouc

128 08

Vseobecna Fakultni Nemocnice V Praze, Prague

260-0801

National Hospital Organization Chibahigashi National Hospital, Chiba

060-8648

Hokkaido University Hospital, Sapporo

807-8556

Hospital of the University of Occupational and Environmental Health, Japan, Kitakyushu-Shi

830-0011

Kurume University Hospital, Kurume-Shi

960-1295

Fukushima Medical University Hospital, Fukushima

981-3205

JCHO Sendai Hospital, Sendai

326-0843

Japanese Red Cross Ashikaga Hospital, Ashikaga-Shi

113-8431

Juntendo University Hospital, Bunkyō-Ku

565-0871

Osaka University Hospital, Suita-Shi

All Listed Sponsors
lead

HI-Bio, A Biogen Company

INDUSTRY

NCT05065970 - Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab (MOR202) in IgA Nephropathy | Biotech Hunter | Biotech Hunter